1,8-Cineole / NRF2 Cancer Research Results

1,8-Cin, 1,8-Cineole: Click to Expand ⟱
Features:

1,8-Cineole — 1,8-cineole, also called eucalyptol, is a volatile bicyclic monoterpene ether and major active constituent of eucalyptus oil and several other aromatic plant oils (other plants such as oregano (Origanum spec.), thyme (Thymus spec.), guava (Psidium pohlianum) or sage (Salvia spec.)). Eucalyptus oil used for medicinal applications should contain at least 70% of 1,8-Cineol. It is best classified as a small-molecule phytochemical / essential-oil monoterpenoid rather than as a botanical extract. Its main established human-use identity is respiratory anti-inflammatory / mucolytic support, while its oncology relevance is preclinical and concentration-limited.

Primary mechanisms (ranked):

  1. Apoptosis induction through ↓ Akt / ↓ survivin with ↑ p38 MAPK, ↑ cleaved caspase-3, and ↑ cleaved PARP in colorectal cancer models.
  2. Suppression of PI3K / Akt / mTOR signaling linked to reduced migration and invasion in skin cancer models.
  3. Anti-proliferative and cell-cycle stress effects, including reduced BrdU incorporation and tumor-growth suppression in xenograft models.
  4. Oxidative-stress-linked apoptosis or senescence in selected models; this appears model-dependent and may require high concentrations.
  5. Anti-inflammatory cytokine suppression, including ↓ TNF-α and ↓ IL-1β, which is better established in inflammatory/airway contexts than as a direct cancer mechanism.
  6. Membrane penetration / formulation effects, relevant to delivery and topical/transmucosal exposure but not a cancer-selective mechanism.

Bioavailability / PK relevance: 1,8-cineole is orally and inhalationally absorbed and undergoes rapid systemic distribution, with CYP3A-mediated oxidation as an important metabolic route. Enteric-coated oral preparations can deliver measurable tissue exposure in airway/nasal tissues, but oncology-relevant systemic concentrations are not established.

In-vitro vs systemic exposure relevance: Many anticancer studies use millimolar-range in-vitro concentrations or concentrated essential-oil fractions, which likely exceed routine achievable systemic exposure from conventional oral or inhaled use. Direct cancer-cell effects should therefore be marked as exposure-constrained unless a delivery formulation is specified.

Clinical evidence status: Preclinical oncology only. There is cell-line and animal/xenograft evidence for anticancer activity, but no established cancer-directed clinical efficacy. Human clinical deployment is mainly respiratory/supportive use of eucalyptus oil or purified 1,8-cineole preparations, not antineoplastic therapy.

1,8-Cineole Cancer Mechanism Summary

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Akt / survivin / p38 apoptosis axis ↓ Akt; ↓ survivin; ↑ p38; ↑ cleaved PARP; ↑ caspase-3 Limited direct selectivity data G Apoptosis and tumor-growth suppression Core anticancer mechanism in colorectal cancer models; likely high-concentration dependent.
2 PI3K / Akt / mTOR invasion axis ↓ PI3K; ↓ Akt; ↓ mTOR; ↓ migration; ↓ invasion Not well established G Anti-invasive and anti-metastatic signaling Mechanistically central in skin cancer models; therapeutic translation remains preclinical.
3 Cell proliferation and cell-cycle stress ↓ proliferation; ↓ BrdU incorporation; ↑ growth arrest (model-dependent) Unclear G Cytostatic pressure and reduced tumor expansion Observed across multiple cancer models, but dose ranges often exceed routine clinical exposure.
4 ROS-linked apoptosis or senescence ↑ ROS (model-dependent); ↑ oxidative stress-linked death or senescence May show anti-inflammatory or antioxidant-context effects G Context-dependent oxidative stress leverage Evidence is mixed by model and preparation; stronger when using 1,8-cineole-rich extracts or high concentrations.
5 Inflammatory cytokine signaling Potential ↓ NF-κB-linked inflammatory support (context-dependent) ↓ TNF-α; ↓ IL-1β; ↓ airway inflammatory signaling R/G Anti-inflammatory modulation Better supported for airway/inflammatory disease than for direct cancer-cell killing.
6 Membrane penetration and formulation effects May alter uptake of co-administered compounds (context-dependent) Potential irritation or barrier disruption at high topical exposure R/G Delivery modifier Important for essential-oil and topical/transmucosal contexts; not inherently tumor-selective.
7 CYP3A metabolism and drug-interaction constraint ↔ direct anticancer effect CYP3A-mediated oxidation; systemic clearance R/G PK limitation Potential relevance for co-administered drugs, especially where CYP3A substrates or inhibitors are involved.
8 Clinical Translation Constraint High in-vitro concentrations may not map to systemic dosing GI irritation, CNS toxicity risk in overdose, pediatric laryngospasm/seizure precautions G Translation barrier Oncology status preclinical; established human use is respiratory/supportive rather than antineoplastic.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
6474- 1,8-Cin,    Molecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation
- in-vitro, Nor, HT29 - in-vivo, Nor, NA - in-vivo, IBD, NA
*Inflam↓, *NRF2↑, *antiOx↑, *PPARγ↑, eff↑,
6461- 1,8-Cin,    1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases
- Review, AD, NA - Review, Var, NA
*Inflam↓, *antiOx↑, *neuroP↑, *BioAv↑, *Half-Life↝, *toxicity↓, *PGE2↓, *TNF-α↓, *IL1β↓, *NO↓, *NF-kB↓, *PPARγ↓, COX2↓, *ROS↓, *SOD↑, *Catalase↑, *TAC↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *NADPH↑, *GPx↑, *AntiBio↑, *eff↑, *AntiFungal↑, *AntiViral↑, *TRPA1↑, eff↑, TumCCA↑, ROS↑, MAPK↝, mTOR↝, Apoptosis↑, survivin↓, Akt↓, p38↑, cl‑PARP↑, cl‑Casp3⇅, P53↑, BAX↑, Cyt‑c↑, Casp9↑, Dose↝, *Aβ↓, *tau↓, *GSK‐3β↓, *BACE↓, *cardioP↑, MFN2↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

MFN2↑, 1,  

Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   cl‑Casp3⇅, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   MAPK↝, 1,   p38↑, 1,   survivin↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↝, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 2,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiBio↑, 1,   TRPA1↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 1,   SOD↑, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis ⓘ

NADPH↑, 1,   PPARγ↓, 1,   PPARγ↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   eff↑, 1,   Half-Life↝, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,  
Total Targets: 33

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:409  Target#:226  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page